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Abstract: c-Jun N-terminal kinase (JNK) is activated by various brain insults and is implicated
in neuronal injury triggered by reperfusion-induced oxidative stress. Some JNK inhibitors
demonstrated neuroprotective potential in various models, including cerebral ischemia/reperfusion
injury. The objective of the present work was to study the neuroprotective activity of a new specific
JNK inhibitor, IQ-1S (11H-indeno[1,2-b]quinoxalin-11-one oxime sodium salt), in the model of global
cerebral ischemia (GCI) in rats compared with citicoline (cytidine-5′-diphosphocholine), a drug
approved for the treatment of acute ischemic stroke and to search for pleiotropic mechanisms of
neuroprotective effects of IQ-1S. The experiments were performed in a rat model of ischemic stroke
with three-vessel occlusion (model of 3VO) affecting the brachiocephalic artery, the left subclavian
artery, and the left common carotid artery. After 7-min episode of GCI in rats, 25% of animals died,
whereas survived animals had severe neurological deficit at days 1, 3, and 5 after GCI. At day 5 after
GCI, we observing massive loss of pyramidal neurons in the hippocampal CA1 area, increase in lipid
peroxidation products in the brain tissue, and decrease in local cerebral blood flow (LCBF) in the
parietal cortex. Moreover, blood hyperviscosity syndrome and endothelial dysfunction were found
after GCI. Administration of IQ-1S (intragastrically at a dose 50 mg/kg daily for 5 days) was associated
with neuroprotective effect comparable with the effect of citicoline (intraperitoneal at a dose of
500 mg/kg, daily for 5 days).The neuroprotective effect was accompanied by a decrease in the number
of animals with severe neurological deficit, an increase in the number of animals with moderate
degree of neurological deficit compared with control GCI group, and an increase in the number of
unaltered neurons in the hippocampal CA1 area along with a significant decrease in the number
of neurons with irreversible morphological damage. In rats with IQ-1S administration, the LCBF
was significantly higher (by 60%) compared with that in the GCI control. Treatment with IQ-1S
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also decreases blood viscosity and endothelial dysfunction. A concentration-dependent decrease
(IC50 = 0.8 ± 0.3 µM) of tone in isolated carotid arterial rings constricted with phenylephrine was
observed after IQ-1S application in vitro. We also found that IQ-1S decreased the intensity of the lipid
peroxidation in the brain tissue in rats with GCI. 2.2-Diphenyl-1-picrylhydrazyl scavenging for IQ-1S
in acetonitrile and acetone exceeded the corresponding values for ionol, a known antioxidant. Overall,
these results suggest that the neuroprotective properties of IQ-1S may be mediated by improvement
of cerebral microcirculation due to the enhanced vasorelaxation, beneficial effects on blood viscosity,
attenuation of the endothelial dysfunction, and antioxidant/antiradical IQ-1S activity.
Keywords: c-Jun N-terminal kinase; JNK inhibitor; neuroprotection; model of global cerebral
ischemia; antiradical activity; cerebral microcirculation
1. Introduction
c-Jun N-terminal kinase (JNK) is a critical mitogen activated protein kinase (MAPK) modulated
by various brain stimuli and implicated in neuronal injury triggered by reperfusion-induced oxidative
stress [1]. Three distinct JNKs, designated as JNK1, JNK2, and JNK3, have been identified, and at least
10 different splicing isoforms exist in the mammalian cells [2]. JNK3 is found almost exclusively in
the brain [3] but it is not dominant, as JNK3 knockout results only in a weak attenuation of the total
JNK pool in the brain tissue [4]. Increased JNK phosphorylation and JNK activity in the hippocampus
have been reported after cerebral ischemia and reperfusion injury [5,6]. Sustained JNK activation has
been shown to be associated with neuronal death and apoptosis following ischemic stroke. Various
nonprotein synthetic inhibitors of JNK enzymatic activity are described, including SP600125, AS601245,
IQ-1S, SR-3306, and SU3327 as well as protein and nonprotein molecules inhibiting interactions of
JNKs with their substrates, folding proteins, and/or cell organelles [7–13]. Some of them demonstrated
neuroprotective activity in the animal models of stroke [14–17]. The specific JNK inhibitors selectively
attenuate the activity of brain-expressed JNK3 and/or JNK signaling pathway that form in pathological
conditions of ischemia/reperfusion [13,18]. These data suggest that searching for the efficacious
neuroprotectors among JNK inhibitors is a promising area for the development of approaches to
treatment of acute ischemic and reperfusion brain injury [13,18].
A new specific JNK inhibitor, IQ-1S (11H-indeno[1,2-b]quinoxalin-11-one oxime sodium salt),
has high affinity to JNK3 compared with its affinity to JNK1/JNK2 [9,19]. Evaluation of the therapeutic
potential of IQ-1S showed that the compound could inhibit matrix metalloproteinase 1/3 gene expression
in human synoviocytes and significantly attenuated development of murine collagen-induced
arthritis [19]. IQ-1S also suppressed lipopolysaccharide-induced production of proinflammatory
cytokines in a culture of monocytic cells [9]. Moreover, IQ-1S could release nitric oxide (NO) during
its enzymatic metabolism by liver microsomes and serum nitrite/nitrate concentration in mice after
intraperitoneal (i.p.) injection of IQ-1S was increased [20]. It should be noted that JNK signaling pathway
is closely associated with NO production in ischemia and reperfusion [21]. Donors of exogenous NO
decrease S-nitrosylation of mixed-lineage protein kinase 3 (MLK3) triggered by reperfusion and inhibit
activation of JNK-dependent pathway [22]. A NO donor, sodium nitroprusside (SNP), decreases
JNK3 phosphorylation and damage to the hippocampal neurons after global ischemia/reperfusion [23].
Due to the dual action as a JNK inhibitor and a NO-donor, IQ-1S may have therapeutic potential,
which was previously evaluated in an animal stroke model. In the model of focal cerebral ischemia
in mice, IQ-1S demonstrated remarkable reductions in neurological deficit and infarct volume as
compared with vehicle-treated mice after 2 days of reperfusion [20].
Updated Stroke Treatment Academic Industry Roundtable (STAIR) recommendations set a
variety of requirements for research of promising neuroprotectors [24]. One of these requirements
demands that efficacy of a potential neuroprotector must be established in at least two species using
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both histological and behavioral outcome measures. The aim of the present work was to study the
neuroprotective activity and the mechanisms of IQ-1S action in the model of transient global cerebral
ischemia (GCI) in rats. We also evaluated the content of lipid peroxidation products in the brain tissue,
local cerebral blood flow (LCBF), blood viscosity, hematocrit, parameters of erythrocyte aggregation,
erythrocyte elongation index, indices of plasma hemostasis, and vasodilator activity of endothelium in
IQ-1S-treated and nontreated rats at day 5 after GCI. Because previous data demonstrated that JNK
contributes to the regulation of vascular function, including vascular smooth muscle contraction [25],
an effect of IQ-1S on the vascular tone of the isolated carotid artery rings in vitro was also studied.
2. Results
2.1. Effects of IQ-1S on Survival and Neurological Status
In group of sham-operated animals, spontaneous motor activity decreased in 38% and 13% of
animals at days 1 and 3 after surgical intervention, respectively; mean scores of neurological deficit
were 0.4 ± 0.2 and 0.1 ± 0.1 for these time points, respectively. To day 5 of the study, no further changes
in neurological status were found (Figure 1A).
After GCI reproduction in 45 rats of the control group for 5 days, 10 rats died (mortality rate
was 22%). In experimental group administered with IQ-1S, seven (15%) rats of 46 animals died after
ischemia episode. In the group of animals with i.p. introduction of citicoline after GCI, two rats
(10%) of 20 animals died. No significant differences in the levels of mortality between groups were
found (Table 1).
Table 1. The effects of IQ-1S and citicoline on mortality of animals after global cerebral ischemia (GCI).
Group of Animals Number of Dead Animals (% of Total Number)
Day 1 Day 3 Day 5
Sham-operated (n = 23) 0 (0) 0 (0) 0 (0)
Control (n = 46) 4 (9) 9 (20) 10 (22)
IQ-1S, 50 mg/kg (n = 46) 5 (11) 7 (15) 7 (15)
Citicoline, 500 mg/kg (n = 20) 0 (0) 2 (10) 2 (10)
In control animals with GCI, neurological symptoms in the early reperfusion period (for the first 3 h)
were characterized by the predominance of cerebral symptoms: disruption of spontaneous breathing,
failure to maintain posture, areflexia, and hypertonia of the extremities. In surviving animals,
the functions of the central neural system gradually restored and the neurological abnormalities
regressed during the first hours after GCI. However, abnormalities in the muscle tone and motor
coordination, slow or absent reflexes, and ptosis persisted up to day 5; some animals presented with
convulsive disorder. At day 1 after reperfusion, mean score of neurological deficit was 8.4± 0.9. To days
3 and 5, mean scores of neurological deficit decreased to 82% and 61%, respectively, relative to the
corresponding value at day 1; during the entire period of observation, significant differences persisted
compared with the group of sham-operated animals (Figure 1A). At day 1 after GCI, all survived
rats of control group had severe neurological deficit. At day 3 and day 5, neurological disorders
persisted (Figure 1B).
In rats administered with IQ-1S at day 1 after GCI, mean score of neurological deficit was 6.1
± 0.5 and was by 27% lower than the corresponding value in the control group. To days 3 and 5,
mean scores of neurological deficit decreased to 4.2 ± 0.4 and 3.0 ± 0.3 suggesting that this indicator
was significantly lower than control values by 39% and 41%, respectively (Figure 1A). In response to
IQ-1S, at day 1 after GCI, the number of animals with severe neurological deficit significantly decreased
(Figure 1B).
In the group of animals administered with citicoline, a drug approved for the treatment of acute
ischemic stroke, mean score of neurological deficit at day 1 after reperfusion was 5.5 ± 0.8, which was
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34% lower than the control value. To days 3 and 5, mean scores of neurological abnormalities decreased
by 22% and 40% compared with the corresponding value at day 1 and were lower than the control
values by 38% and 35%, respectively. During all periods of the study, the indicator significantly differed
from the corresponding value in the group of control animals (Figure 1A). In response to citicoline at
day 1 after reperfusion, the number of animals with severe neurological deficit significantly decreased
(Figure 1B).Molecules 2019, 24, x FOR PEER REVIEW 5 of 24 
 
 
Figure 1. Effects of IQ-1S (50 mg/kg, i.g.) and citicoline (500 mg/kg, i.p.) on average score of 
neurological deficit (A) and animal distribution for degree of neurological deficit (severe, moderate, 
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the control animals (A: # р < 0.05 at different times; B: # р < 0.05 for subgroups “severe” only). 
Figure 1. Effects of IQ-1S (50 mg/kg, i.g.) and citicoline (500 mg/kg, i.p.) on average score of neurological
deficit (A) and animal distribution for degree of neurological deficit (severe, moderate, and mild) (B).
* p < 0.05 as compared with the sham-operated animals; + p < 0.05 as compared with the control animals
(A: # p < 0.05 at different times; B: # p < 0.05 for subgroups “severe” only).
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2.2. Effects of IQ-1S on the Morphological Structure of the CA1 Hippocampal Area
In sham-operated animals, the neurons of the CA1 hippocampal area had a round shape and
homogenous staining of the cytoplasm and the nucleus, suggesting the absence of pathomorphological
alterations. Numerical density of the neurons was 2,875 ± 121 cells per mm2 (Figure 2A,B). Modeling of
GCI led to massive loss of the neurons in the pyramid layer of CA1 hippocampal region at day 5 after
reperfusion. This manifested as a reduction of numerical neurons by 29% compared with sham-operated
animals. Among surviving neurons, 42% of the cells were piknotic. Besides, we observed the layer
disorganization; 6% of the cells had rim of pericellular edema of the neurons, and many neurons had
eosinophilic cytoplasm (Figure 2A–D).
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Figure 2. Effects of IQ-1S (50 mg/kg, i.g.) and citicoline (500 mg/kg, i.p.) on the quantitative neuronal
density (A), percentage of unchanged neurons (B), percentage of neurons with pericellular edema (C)
and illustrations of CA1-zone of hippocampus (D) in rats at day 5 after GCI. * p < 0.05 as compared with
the sham-operated animals; + p < 0.05 as compared with the control. Black arrows indicate neurons
with pericellular edema; white arrows indicate pyknotic eosinophilic neurons.
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Comparison of the cell composition and neuronal morphology in the hippocampal CA1 region in
the control group and in the experimental group with IQ-1S administration showed an increase in the
numerical density of the neurons by 39% and over two-fold increase of unaltered neurons due to a
decrease in the number of neurons with pathomorphological changes. Indeed, the number of neurons
with pericellular edema in rats treated with IQ-1S was by 60% lower than the corresponding value
in the control group (Figure 2C,D). Citicoline did not affect the number of neurons with pericellular
edema (Figure 2C).
Therefore, IQ-1S, when administered to animals intragastrically (i.g.) at a dose of 50 mg/kg,
exerted a pronounced neuroprotective effect seen as significant increases in the numerical density of
the neurons, the number of vital pyramidal neurons, and a decrease in the number of neurons with
pericellular edema in the hippocampal CA1 region. The extents of neuroprotective effects of IQ-1S at a
dose of 50 mg/kg and citicoline at a dose of 500 mg/kg were comparable.
2.3. Effects of IQ-1S on Lipid Peroxidation in Cerebral Tissue
Lipid peroxidation products (LPPs) can serve as second messengers that evoke proapoptotic
responses via covalent modification of the key sensors in neuronal tissue [26]. Therefore, as the next
step of experiments, we evaluated the LPPs in the brain tissue of experimental animals after GCI.
In control group at day 5 after GCI, we found a significant increase in diene conjugates and triene
conjugates by 22% and 30%, respectively, compared with the corresponding values in sham-operated
animals (Figure 3). IQ-1S (50 mg/kg, i.g.) decreased the intensity of the LPP formation in the brain
tissue; the levels of diene conjugates and triene conjugates were significantly lower than in control by
16% and 25%, respectively (Figure 3). Citicoline (500 mg/kg, i.p.) also caused decreases in the levels of
diene conjugates and triene conjugates (by 26% and 32%, respectively) in the brain tissue (Figure 3).
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Figure 3. Effects of IQ-1S (50 mg/kg, i.g.) on contents of diene conjugates (OD232/mg of lipids) and
triene conjugates (OD270/mg of lipids) in the brain tissue in rats at day 5 after GCI. * p < 0.05 as compared
with the sham-operated animals; + p < 0.05 as compared with the control.
2.4. Antiradical Effect of IQ-1S
The values of specific reaction rates of the studied compounds with 2.2-diphenyl-1-picrylhydrazyl
(DPPH) are presented in Figure 4 and Table 2. DPPH radical was stable in all used solvents. During 1-h
registration in the presence of DPPH alone, no more than 0.5% of DPPH underwent transition to the
nonradical form. Analysis of obtained data allowed to find that the specific reaction rate for the DPPH
scavenging in ethyl acetate for IQ-1S did not significantly differ from ionol, whereas, in acetonitrile and
acetone, it significantly exceeded the corresponding values for this control antioxidant (Figure 4A–C).
On the contrary, specific reaction rate for DPPH scavenging in proton solvent ethanol for ionol was
significantly higher than for IQ-1S (Figure 4D).
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Figure 4. Decay of DPPH radical in control sample and during the reaction with IQ-1S and ionol in
acetone (A), in acetonitrile (B), in ethyl acetate (C), and in ethanol (D). The initial concentrations of
DPPH radical and IQ-1S or ionol were always the same.
Table 2. Reaction rate constants (min−1) DPPH with IQ-1S and ionol in various solvents.
Solvent IQ-1S Ionol
Ethyl acetate 0.0802 ± 0.0148 0.0448 ± 0.0126
Acetonitrile 0.0395 ± 0.0028 + 0.0031 ± 0.0005
Acetone 0.0123 ± 0.0013 + 0.0017 ± 0.0008
Ethanol 0.0021 ± 0.0011 + 0.0456 ± 0.0013
+ p < 0.05 as compared with ionol.
2.5. Effects of IQ-1S on LCBF in Cerebral Cortex, Mean Arterial Blood Pressure, and Heart Rate
The level of LCBF in intact rats was 1900 ± 191 blood perfusion unit (BPU). In the control group at
day 5 after GCI, LCBF decreased by almost two times compared with sham-operated animals. In rats
of the experimental group after IQ-1S administration (50 mg/kg, i.g.), LCBF was significantly higher
(by 60%) compared with that in the control. No significant differences in the values of mean arterial
blood pressure and heart rate after GCI were found between groups at day 5 (Table 3).
Table 3. The effects of IQ-1S (50 mg/kg) on LCBF (BPU, a blood perfusion unit), mean arterial blood
pressure (ABP, mm Hg), and heart rate (HR, min−1) in rats at day 5 after GCI.
Group LCBF ABP HR
Sham-operated (n = 5) 1900 ± 191 93 ± 9 358 ± 10
Control (n = 9) 888 ± 80 * 97 ± 2 376 ± 13
IQ-1S (n = 10) 1424 ± 213 + 94 ± 4 352 ± 12
* p < 0.05 as compared with the corresponding values in sham-operated rats; + p < 0.05 as compared with the
corresponding values in control rats.
2.6. Effects of IQ-1S on Hemorheological Parameters
In the control group of animals at day 5 after creation of GCI model, we observed a significant
increase in blood viscosity in the entire diapason of shear rates (by 14–16%) compared with
sham-operated rats (Figure 5). In animals of the control group, we found a significant increase
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in plasma viscosity (by 3%) and hematocrit (by 7%) relative to the corresponded values in the group of
sham-operated animals (Table 4). Administration of IQ-1S (50 mg/kg, i.g.) to rats with GCI limited an
increase in whole blood viscosity in a wide range of shear rates (from 60 to 450 s−1). Blood viscosity was
lower than that in control by 9–11% (Figure 5). Plasma viscosity and hematocrit values in animals with
i.g. administration of IQ-1S were preserved at the levels of those in sham-operated animals (Table 4).
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Figure 5. Effects of IQ-1S (50 mg/kg, i.g.) on the viscosity of whole blood (mPa·s) in rats at day 5 after
GCI. * p < 0.05 as compared with the sham-operated animals; + p < 0.05 as compared with the control.
Table 4. The effects of IQ-1S (50 mg/kg, i.g.) on plasm viscosity, hematocrit (Ht), and parame ers of
ery hrocyte aggregation in the shear flow (Ct and Cs) in rats at day 5 after GCI.
Group Plasma Viscosity, mPa·s Ht, % Ct, s Cs, mPa
Sham-operated (n = 5) 1.16 ± 0.01 42 ± 1 9.3 ± 0.3 144.1 ± 4.2
Control (n = 6) 1.19 ± 0.01 * 45 ± 1 * 10.6 ± 0.7 145.6 ± 11.3
IQ-1S (n = 6) 1.17 ± 0.01 42 ± 1 + 9.6 ± 0.2 151.8 ± 4.6
* p < 0.05 as compared with the corresponding values in sham-operated rats; + p < 0.05 as compared with the
corresponding values in control rats.
The study of erythrocyte aggregation in shear flow in animals with GCI did not show any
significant differences between sham-operated rats, control rats, and animals administered with IQ-1S
(Table 4). The study of erythrocyte deformability in animals with GCI showed a decrease of elongation
index by 2–4% in the presence of shear s ress of 1–3 Pa in animals of t e control group compa d w th
that in sham-o erated animals, but these chang s did not reach statistical significance. I group of
animals administered with IQ-1S, no changes in erythrocyte elon ation index were fo nd (Table 5).
Table 5. The effects of IQ-1S (50 mg/kg, i.g.) on the erythrocyte elongation index in rats at day 5
after GCI.
Group Shear Stress, Pa
1 3 7 10 20
Sham-operated (n = 5) 0.201 ± 0.007 0.354 ± 0.005 0.453 ± 0.004 0.486 ± 0.003 0.533 ± 0.002
Control (n = 6) 0.192 ± 0.006 0.348 ± 0.005 0.449 ± 0.004 0.483 ± 0.003 0.532 ± 0.003
IQ-1S (n = 6) 0.198 ± 0.006 0.356 ± 0.005 0.455 ± 0.003 0.487 ± 0.002 0.532 ± 0.003
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2.7. Effects of IQ-1S on Vasodilator Activity of Endothelium
Evaluation of the endothelial function in sham-operated rats showed that a brief decrease in
systolic blood pressure, followed by its rapid recovery, occurred in response to intravenous (i.v.) bolus
introduction of acetylcholine (Ach) at a dose of 40 µg/kg (area above the curve of blood pressure
decrease, SAch, was 853 ± 153 mm Hg•sec). In response to i.v. bolus administration of SNP at a dose of
30 µg/kg, similar response of arterial blood pressure occurred (area above the curve of blood pressure
decrease, SSNP, was 1900 ± 282 mm Hg•sec). The index of vasodilatory activity (IVA) calculated as
ratio of SAch/SSNP in sham-operated animals was 0.41 ± 0.04 (Figure 6).
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Figure 6. Effects of IQ-1S (50 mg/kg, i.g.) and citicoline (500 mg/kg, i.p.) on the endothelium-dependent
vasodilation, induced by acetylcholine (SAch) and SNP (SSNP) (A), and index of vasodilatory activity
(IVA = SAch/SSNP) (B) in rats at day 5 after GCI. * p < 0.05 as compared with the sham-operated animals;
+ p < 0.05 as compared with the control.
In rats with GCI, endothelium-dependent reduction in systolic blood pressure in response to
acetylcholine was lower. Indeed, there was a significant 29% decrease in SAch compared with the
corresponding values in group of sham-operated rats. In the absence of changes in SSNP, IVA decreased,
which suggeste the developme t of endothelial dysfunction in rats after GCI (Figure 6).
In group of GCI rats administered with IQ-1S at a dose of 50 mg/kg, t e value of SAch was
significa tly higher tha that in the group of control animals, which was seen as expected increase in
IVA by 25% compared with that in the control (Figure 6). Citicoline in these conditions did not affect
the study parameters of endothelial function in rats after GCI.
2.8. Effects of IQ-1S on Tonus of Isolated Carotid Artery Rings
In our study, no significant differences between the mean values of arterial blood pressure were
observed in the experimental groups (Table 3). These findings suggest that the changes in the perfusion
pressure do not modulate the effects of IQ-1S on LCBF. In search for other mechanisms of LCBF
increase, the effects of IQ-1S on the vascular tone of carotid arteries in vitro were studied. When IQ-1S
was applied at concentrations ranging from 0.001 to 100 µM to carotid arterial rings constricted with
phenylephrine, concentration-dependent decrease (IC50 = 0.8 ± 0.3 µM) in the vascular smooth muscle
ring tone was observed (Figure 7).
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Figure 7. The effects of IQ-1S on the tone of the vascular rings, isolated from the carotid artery and
constricted by phenylephrine (1 µM).
2.9. Effects of IQ-1S on Indices of Plasma Hemostasis
At day 5 after GCI, a clear tendency to increasing fibrinogen level (Fbg) and shortening thrombin
time (TT) was observed in control group relative to sham-operated animals (Table 6). Parameters
of activated partial thromboplastin time (aPTT) and prothrombin time (PT) did not differ from the
corresponding values in sham-operated animals. In the presence of course intragastric administration of
IQ-1S compared with control group of rats, the study parameters of plasma hemostasis did not change.
Table 6. The effects of IQ-1S (50 mg/kg, i.g.) on fibrinogen (Fbg), the activated partial thromboplastin
time (aPTT), prothrombin time (PT), and thrombin time (TT) in rats at day 5 after GCI.
Group Fbg, g/L aPTT, s PT, s TT, s
Sham-operated (n = 5) 2.68 ± 0.28 17.8 ± 0.7 25.3 ± 0.5 32.8 ± 0.4
Control (n = 9) 3.30 ± 0.21 17.9 ± 0.5 26.3 ± 0.6 24.5 ± 3.9
IQ-1S (n = 10) 3.04 ± 0.14 17.3 ± 0.5 26.3 ± 0.3 27.9 ± 3.0
3. Discussion
Cerebral ischemia has several forms, depending on the nature and severity of cerebrovascular
insufficiency. A number of experimental models was developed, in which the blood flow is interrupted
sharply or slowly, in a whole or in a part, focally or globally, as well as permanently or transiently [27].
The models of cerebral ischemia are divided into two groups based on the extent of brain involved in
ischemia: focal cerebral ischemia (FCI) and GCI [28].
Updated STAIR recommendations demand compliance with various requirements of preclinical
studies for promising neuroprotectors [24]. In compliance with these requirements, proof of the
efficacy of new neuroprotectors have to be obtained in no less than two species of animals. Besides,
some authors suggest the necessity to study promising neuroprotectors in different models of cerebral
ischemia [29–31]. In the opinion of Papadakis et al. [32], models of GCI cause selective neuronal death
in the particular regions of the hippocampus and can be used to isolate pathways involved in the
neuronal vulnerability or survival. GCI rapidly causes a cascade of events in the vulnerable regions of
the brain, including the hippocampus, striatum, cerebral cortex, and cerebellum, that eventually lead
to neuronal damage and death. Damage to the affected tissue can often leads to permanent impairment
of mental and physical faculties, the shutdown of essential functions, or even death [33,34].
In our study, the 3VO model of GCI [35] was chosen for the experiments for the following
reasons. Since this model certainly reproduces neuronal damage in CA1 region of the hippocampus,
it allows one to obtain morphology data necessary to assess the possible neuroprotective activity
of IQ-1S. Additionally, in the reproduction of this model, clear presentation of neurological deficit
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occurs [35,36], allowing one to investigate the potential mechanisms of IQ-1S action and the IQ-1S effects
on neurological status. This model has been previously approved for the evaluation of neuroprotective
effects of various compounds [37]. Citicoline, a neuroprotector with pleiotropic action, serves as a
comparison drug. The efficacy of citicoline in acute ischemic stroke may be due to stabilization of the
cell membranes, attenuation of glutamate excitotoxicity and oxidative stress, suppression of apoptosis,
and elimination of endothelial dysfunction [38–40].
Reproduction of GCI model resulted in death of 25% of animals as well as in the development of
severe symptoms of brain damage in survived animals persisting for up to five days. Slight spontaneous
reduction of the severity of neurological abnormalities occurred to day 5 after reperfusion.
Neuroprotective activity of IQ-1S was confirmed by studying the dynamics of neurological status
in the postischemic period in animals with GCI. In case of administration of IQ-1S, the surviving
animals had less severe neurological deficits in the early reperfusion period and the recovery of their
neurological status was promoted. In surviving animals administered with IQ-1S and in the positive
control group with administration of citicoline, the improvements of neurological status recovery were
similar. We observed a decrease in mean score of neurological deficit relative to the control group.
At day 1, we documented a significant decrease in the number of animals with severe neurological
disorders with a corresponding increase in the number of animals with moderate degree of neurological
deficit. Death rates were lower both in IQ-1S- and in citicoline-treated rats compared with control
group, but these differences did not reach statistical significance. Our study confirms earlier data on
the neuroprotective activity of IQ-1S in the FCI model in mice [20]. In these experiments, IQ-1S-treated
mice demonstrated markedly reduced neurological deficit and infarct volumes as compared with
vehicle-treated mice after 2 days of reperfusion.
Morphology data in the model of GCI confirm neuroprotective action of IQ-1S. In the settings of
the GCI model used in our experiments, complete cessation of blood flow occurs in all parts of the
brain without residual and collateral circulation [35]. During the 7-min episode of ischemia followed
by reperfusion, diffuse damage to neural tissue occurs with predominant death of the neurons in the
parts of the brain sensitive to ischemia, including pyramidal neurons of CA1 and CA3 areas in the
hippocampus, small neurons of striatum and basal ganglia, and neurons in the layers II, III, and V
of the neocortex [35,36]. Based on the analysis of neuroprotective activity of IQ-1S in rats with GCI,
the CA1 hippocampal area was chosen as the neurons in this zone are most vulnerable to harmful
effects of ischemia/reperfusion [41,42]. In the CA1 hippocampal region in the animals administered
with IQ-1S, we observed a clear increase in numerical density of neurons, an increase in the number of
unaltered neurons, and a significant decrease in the number of neurons with irreversible morphological
damage such as pericellular edema suggesting a pronounced neuroprotective effect of the studied
compound. Therefore, IQ-1S in the model of GCI demonstrated a significant neuroprotective activity,
which manifested in positive effects on neurological status and morphological parameters in the CA1
area of the hippocampus.
The significance of the neuroprotective potential of IQ-1S was clearly demonstrated compared
with citicoline whose neuroprotective effects have been proven experimentally [38–40] and in clinical
trials [43,44]. Studying the neurological deficit, morphology, and lipid peroxidation products in the
brain tissue did not show significant differences in the effects of IQ-1S and citicoline on these parameters
despite citicoline being used in i.p. dose exceeding that of IQ-1S by 10 times. Therefore, the effects of
IQ-1S and citicoline were comparable.
To exert direct neuroprotective action, the substance must penetrate the blood–brain barrier (BBB)
in concentrations sufficient for therapeutic effect. Parameters of the transport through the BBB are
known for the compounds, which are potential neuroprotectors [45]. We [20] calculated the following
parameters of IQ-1S molecule to determine the possibility of the penetration through the BBB: the
octanol/water distribution coefficient (aLogP), polar surface area of molecule (tPSA), and the number of
rotating bonds (Nrot). These calculations allowed us to determine the good ability of IQ-1S molecules
to pass through the BBB.
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Based on the analysis of possible direct neuroprotective/cytoprotective effect of IQ-1S, the ability
of the substance to inhibit JNKs should be considered first of all [9]. JNKs are involved in many
neuropathological signaling events and play a key role in the regulation of survival of brain tissues
in health and disease [46]. The JNK signaling pathway plays a critical role in mediation of apoptosis
in ischemia and reperfusion of the brain [34]. Numerous works demonstrate the increases in JNK
phosphorylation and JNK-dependent signaling pathway activity after global and focal ischemia of the
brain in rats and mice [13,20,47–51]. In stroke, activation of JNK aggravates brain damage, triggering
inflammation and contributing to ischemic death of the cells [52]. An important role of JNK in
the mechanisms of apoptosis of neuronal cells is confirmed by the experiments on knockout mice:
permanent occlusion of the middle cerebral artery significantly expands the infarcted area in jnk1-/-
knockout mice [4]. Further studies are needed to examine the antiapoptotic effect of IQ-1S in models of
ischemia/reperfusion.
Currently, various nonprotein synthetic inhibitors of enzymatic JNK activity are described
(SP600125, AS601245, IQ-1S, SR-3306, and SU3327) as well as protein and nonprotein molecules
suppressing interaction between JNKs and their substrates, JNK and folding proteins and/or
cellular organelles [7–13]. Some of them showed neuroprotective action in the models of stroke
in animals [14–17]. IQ-1S is one of the most specific nonpeptide JNK inhibitors known as it does
not inhibit other kinases [19]. Therapeutic efficacy of this JNK inhibitor was studied in mice with
experimental cerebral ischemia and reperfusion. Introduction of IQ-1S decreased neurological deficit
and infarct volume compared with those in control animals after 2 days of reperfusion [20]. Results
obtained in this work using the model of acute total transitory cerebral ischemia confirmed the efficacy
of IQ-1S as a neuroprotective agent.
Perhaps, the other mechanism contributing to neuroprotective effect of IQ-1S is the ability of the
molecule to be an exogenous NO donor. Data showed that IQ-1S undergoes enzymatic metabolism by
the liver microsomes with a release of NO confirmed by an increase in the nitrate/nitrite content in
blood of the mice after i.p. administration of this compound [20]. The JNK signaling pathway is tightly
coupled with NO production in ischemia and reperfusion [21]. Donors of exogenous NO attenuate
S-nitrosylation of MLK3 triggered by reperfusion and inhibit the activation of the JNK-dependent
pathway [22]. Indeed, SNP decreases JNK3 phosphorylation and neuronal damage in the hippocampus
after global ischemia/reperfusion [53]. The involvement of other kinases into the NO-dependent
modulation of JNK activity is possible. For example, S-nitrosylation of apoptosis signal-regulating
kinase (ASK1) with involvement of endogenous NO activates the JNK-dependent kinase cascade
during cerebral ischemia and reperfusion. At the same time, exogenous NO generated by NO donors
reverses the effects of endogenous NO through the suppression of S-nitrosylation of ASK1 and exerts
neuroprotection during ischemia/reperfusion [54]. Therefore, exogenous NO donors exert protective
effects on the neurons through the regulation of the activities of MLK and ASK1. Other studies also
suggest an important role of ASK1 in the activation of JNK-dependent pathway in ischemia/reperfusion
of the brain [55].
A therapeutic approach based on the use of neuroprotectors with antioxidant properties is well
founded by the concepts of pathogenesis of acute cerebrovascular disorders. Consistent with this idea,
many of the world’s leading laboratories have received evidence confirming the neuroprotective effects
of the antioxidant agents in cerebral ischemia [36,56]. At the same time, the presence of antioxidant
activity is necessary, but insufficient for a molecule to be considered a neuroprotector. Clinical trials of
individual drugs with free radical scavenging activity failed [57–59]. Authors who analyzed failure
of the clinical trials studying the antioxidants with expected neuroprotective properties believe that
the compounds of this class are promising only in the case when the antioxidant exerts multitarget
neuroprotective activity and easily crosses the BBB. Our study allows us to assume that the antioxidant
properties of IQ-1S may underlie its neuroprotective effects in the model of GCI. Indeed, GCI in rats
was accompanied by clear activation of the lipid peroxidation, which manifested as an accumulation of
primary LPPs, diene, and triene conjugates. We found that administration of IQ-1S significantly limited
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the LPPs accumulation in the brain tissue in the postischemic period, which could also contribute to
the neuroprotective effect. This observation agrees with data showing the development of oxidative
stress in patients with abnormal cerebral circulation [60].
Antioxidant properties of IQ-1S to a certain degree may be mediated by the antiradical activity
of the compound. In the cells of the living organisms, the free radical processes may occur both
in aqueous phase [61], and in the lipid phase of the cell membranes [62,63]. To elucidate potential
antioxidant effects of the compounds using DPPH radical scavenging assay, several polar solvents
with various solvating and electron-donating power may be used, including protic amphoteric solvent
ethanol and aprotic bipolar solvents acetone, ethyl acetate, and acetonitrile [64]. Acetonitrile is used
as a relatively nonpolar solvent. In our study, scavenging of free radicals by IQ-1S had the highest
rate in ethyl acetate and acetonitrile. IQ-1S was by 1.7 times more active than ionol in acetonitrile,
but IQ-1S was significantly inferior to ionol in the settings of the reaction with DPPH in regard to
SPLET mechanism in ethanol. Therefore, in aprotic solvents, IQ-1S met or exceeded the antiradical
activity of the standard antioxidant ionol. At the same time, the nature of antiradical activity of IQ-1S
still remains unclear and this question requires further study. Considering the antioxidant effects of
IQ-1S in the GCI model in rats and its antiradical properties, we suggest that the compound could
decrease oxidative stress in the brain issue in ischemia/reoxygenation. Direct cytoprotective effects
of IQ-1S due to JNK inhibition may be complemented with indirect antioxidant effects and effects
associated with improvement of the circulation in the brain tissue.
The postischemic period is characterized by the development of hypoperfusion, which is
mediated by multiple mechanisms including no-reflow phenomenon, which consists of the
obstruction of the downstream microvascular bed after reperfusion of previously occluded arteries.
Postischemic hypoperfusion is attributed to extrinsic compression from edema, endothelial swelling,
and intravascular obstruction due to local activation of leukocytes, platelets, and coagulation [34].
In the present 3VO model of GCI, a severe postischemic hypoperfusion state occurs in the cortex of the
brain [35]. Data obtained in the present study suggest that the hypoperfusion in the cerebral cortex
of rats in this GCI model has steady character and persists up to five days. During this time of the
postischemic period, LCBF values in the cerebral cortex in control rats were by more than twice lower
compared with the corresponding values in the sham-operated animals. In rats administered with
IQ-1S, the LCBF values were by 1.5 times higher than in control animals, suggesting the ability of the
compound to alleviate abnormalities of circulation in the cerebral cortex.
Blood supply of the organ depends on the perfusion pressure, blood viscosity, and the vascular
tone [65]. Perfusion pressure is characterized by the difference between systemic systolic blood
pressure and venous pressure; i.e., it is mostly determined by arterial blood pressure. In our study,
no significant differences between the mean values of arterial blood pressure in the experimental
groups were observed, which probably rules out impact of the changes in the perfusion pressure on
the effects of IQ-1S on LCBF. In search for other mechanisms of LCBF increase, the effects of IQ-1S on
the rheological properties of blood and the tone of the isolated carotid artery in vitro were studied.
In the experiments on the endothelium-denuded rings of the carotid artery, IQ-1S exerted a
dose-dependent vasodilatory effect at the concentrations ranging from 10−9 to 10−4 M. Pharmacokinetic
studies of IQ-1S, performed as preclinical studies, showed that during a period from 1 to 8 h after
i.g. introduction of IQ-1S at a dose of 50 mg/kg, the concentrations of the parent compound in blood
plasma were in the range from 5 to 30 nM/L [66], which corresponds to the concentration range used in
the experiments in vitro, where IQ-1S decreased the tone of the carotid arterial rings preconstricted by
phenylephrine. Therefore, one may assume that IQ-1S can decrease tone of the cerebral blood vessels at
concentrations, present in blood plasma in case of i.g. administration of IQ-1S at the used dose, and this
decrease can contribute to the observed increase in LCBF in rats after GCI. Obtained data agree with
previously described vasodilatory effects of other JNK inhibitor SP600125. For example, JNK activation
is involved in the constriction of rat aortic smooth muscle triggered by norepinephrine, and this
Molecules 2019, 24, 1722 14 of 23
effect is inhibited by SP600125 [67]. In addition, SP600125 also attenuates dexmedetomidine-evoked
contraction of rat thoracic aortic rings without endothelium in a concentration-dependent manner [68].
Abnormal blood rheology could be involved in the pathogenesis of microcirculation disorders
and LCBF decrease in the rat cerebral cortex in the postischemic period. The presence of high blood
viscosity syndrome in patients with acute abnormalities of cerebral circulation is well known [69,70].
In our study, a significant increase in blood viscosity within the entire diapason of shear rates was
observed in control rats at day 5 after GCI. In rats after GCI, high blood viscosity was formed mostly
due to increases in macrorheological parameters, such as hematocrit and plasma viscosity. Recovery of
blood rheological properties with drugs capable to prevent or significantly attenuate the rheological
abnormalities is important, but nowhere near exhausted reserve for therapy of ischemic disorders
of cerebral circulation [71,72]. In our experiments IQ-1S attenuated the extent of rheological blood
abnormalities in rats with GCI. In particular, blood viscosity within the entire range of shear rates was
significantly lower in control and was close to the corresponding values in the group of sham-operated
animals. However, IQ-1S did not significantly affect such microrheological parameters as aggregation
and deformability of the erythrocytes.
Considering the risk of transformation of ischemic stroke into the hemorrhagic one when
neuroprotectors are used together with the agents for thrombolytic therapy [73], we studied the
parameters of plasma hemostasis in rats of experimental and control groups after GCI. IQ-1S did
not show any significant effect on either of study parameters of hemostasis, which may suggest the
minimal risks of its administration when there is danger of hemorrhagic transformation.
Endothelial damage may be an essential element in the pathogenesis of postischemic
hypoperfusion [33]. Endothelial injury reduces the release of NO and prostacyclin, and may induce
endothelin-1 production. These processes lead to increased vascular tone which may further impair
blood flow in the area of the cerebral infarction and collateral vessels, thereby enhancing the ischemic
injury. Endothelin-1 is a highly potent vasoconstrictor [74] to which cerebral microvessels show marked
sensitivity [75]. Plasma levels of endothelin-1 are elevated in ischemic stroke [76] and are associated
with cerebral edema [77]. Using the model of GCI, we demonstrated the presence of endothelial
dysfunction phenomenon, which manifested as a decrease in endothelium-dependent decrease in
systolic blood pressure in response to acetylcholine administration. Moreover, IQ-1S attenuated the
extent of endothelial dysfunction. We assume that a decrease in blood viscosity as well as a reduction of
the endothelial dysfunction in response to IQ-1S all together may result in improved microcirculation,
which is seen as an increase in LCBF in the parietal cortex, i.e., an improvement of blood supply in the
setting of postischemic hypoperfusion.
4. Materials and Methods
4.1. Animals
The study was carried out in accordance with the EU Directive 2010/63/EU concerning the
protection of animals used for scientific purposes and approved by the Animal Care and Use
Committee of Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk NRMC
(protocol No 130092017 from 08.09.17). Experiments were carried out on 142 adult male Wistar rats
(250–280 g) obtained from the Department of Experimental Biological Models of E.D. Goldberg Institute
of Pharmacology and Regenerative Medicine. Rats were housed in groups of five animals per cage
(57 cm × 36 cm × 20 cm) in standard laboratory conditions (ambient temperature of 22 ± 2 ◦C, relative
humidity of 60%, light/dark period 12/12 h a day) in cages with sawdust bedding and provided with
standard rodent feed (PK-120-1, Ltd., Laboratorsnab, Russia), and ad libitum water access.
4.2. Equipment
Rodent ventilator model 7125 (UGO Basile, Gemonio, Italy), temperature control unit HB 101/2
(Spain), homeothermic blanket control unit (Harvard Apparatus, Holliston, MA, USA), MP150
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high-speed data acquisition system with matching amplifiers (Biopac Systems, Inc., Goleta, CA, USA),
rotational viscometer (LVDV-II+ Pro, CP40, Brookfield Engineering Labs Inc., Middleboro, MA, USA),
centrifuge model PC-6, (Dastan, Kyrgyzstan), RheoScanAnD-300 (RheoMeditech Inc., Republic Korea),
rotary microtome HM340E (MICROM International GmbH, Walldorf, Germany), automatic tissue
processing machine STP-120 (MICROM International GmbH, Walldorf, Germany), microscope Carl
Zeiss Axio Lab.A1 and camera Axio Cam ERC5S (Carl Zeiss Microscopy GmbH, Jena, Germany),
spectrophotometer Cary 50 (Varian, USA Australia), CO2 euthanasia device (Open Science, Russia),
and Myobath II (Burghart GmbH, Wedel, Germany), coagulometer KG-4 (Cormay, Łomianki, Poland).
4.3. Chemicals and Drugs
The following chemicals and drugs were used in the work: Propofol-Lipuro (B. Braun Melsungen
AG, Melsungen, Germany), diethyl ether for anesthesia (Kuzbassorghim, Kemerovo, Russia), Tween 80
and sodium nitroprusside dihydrate (Merck, Darmstadt, Germany), 10% neutral formalin and
embedding medium Histomix (BioVitrum, Saint-Petersburg, Russia), hematoxylin (Fluca, St. Louis,
MO, USA), eosin,2,3,5-triphenyl tetrazolium chloride, and ionol (Sigma, St. Louis, MO, USA),
(BioVitrum, Saint-Petersburg, Russia), ethanol (Konstanta-Farm M, Moscow, Russia), acetonitrile
for chromatography, acetone for chromatography, and ethyl acetate (Component-Reactive, Moscow,
Russia), citicoline (Recognan, Alfa Wassermann S.p.A., Bologna, Italy), dimethyl sulfoxide (DMSO),
ethylenediaminetetraacetic acid (EDTA), DPPH, acetylcholine, and phenylephrine (Sigma-Aldrich,
St. Louis, MO, USA), heptane, and isopropanol (Komponent–Reaktiv, Moscow, Russia).
4.4. Study Molecule
Sodium salt of 11H-indeno[1,2-b]quinoxalin-11-one oxime (IQ-1S) was synthesized at the
Department of Biotechnology and Organic Chemistry of Tomsk Polytechnic University, Tomsk,
Russia (batch M314). Chemical structure was confirmed by the methods of mass spectrometry and
nuclear magnetic resonance. Purity of the sample was 99.9%. The animals were administered with
IQ-1S in the form of drug formulation. Drug formulation was the powder of the following composition:
active substance of IQ-1S (28.54%) and the additive agents: carboxymethylcellulose (70.35%) and
Tween 80 (1.01%). Dose of 50 mg/kg was chosen taking into account data of a dose response curve of
IQ-1S effects on neurological scores and ischemic damage in the model of focal cerebral ischemia in
rats as well as data of pharmacokinetic investigation (data are not shown).
4.5. Model of GCI
The model of GCI was reproduced by temporary blocking of blood flow in three great vessels
supplying the brain, namely: the brachiocephalic artery, the left subclavian artery, and the left common
carotid artery [34]. To manage general anesthesia with propofol (10 mg/kg/h), animals were implanted
with a catheter placed in the right femoral vein under brief anesthesia with ethyl ether. After that,
tracheal intubation was performed without damaging the integrity of the trachea. During the surgical
procedure, animals were breathing spontaneously. To ligate the left common carotid artery, an access
from the ventral surface of the neck was used. To ligate the brachiocephalic artery and the left
subclavian artery, the surgical field was access from the first intercostal space was used. To model
GCI, blood flow in the ligated blood vessels was stopped for 7 min. At the moment of spontaneous
breathing secession (after 1 to 1.5 min), the intubation tube was attached to the artificial lung ventilation
apparatus with an open contour. Blood flow was restored by release of the ligatures. The layered
closure of the wound was performed. Upon restoring rhythmical spontaneous breathing, animals
were extubated and returned to their cages with free access to food and water. Sham-operated animals
were subject to similar surgical procedure, but without secession of blood flow through the ligated
blood vessels.
During surgical procedure and during the entire experiment, rectal temperature in the animals
was maintained at 37 ± 0.5 ◦C by using Homeothermic Blanket Control Unit.
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4.6. Experimental Protocol
Animals were assigned to four groups: sham-operated (I, n = 23), control group (II, n = 46/36:
total number/survived animals), experimental group (III, IQ-1S, n = 46/39), group of positive control
(IV, citicoline, n = 20/18). Rats of group III received 50 mg/kg IQ-1S i.g. in 2 mL suspension, rats of
group IV received peritoneal injection of 500 mg/kg citicoline. IQ-1S and citicoline were administrated
30 min prior to modeling GCI, and then once daily for four consequent days. Rats of control and
sham-operated groups received i.g. 2 mL of physiological saline solution containing equal Tween
80 according to the same scheme. Survival and neurological status were assessed at days 1, 3, and 5
after modeling GCI. Survival was assessed in all animals taken in the experiment (135). Neurological
deficit evaluation, histology study, and antioxidant activity measurement were examined in eight
sham-operated rats, 16/13 rats of control group, 16/14 rats of experimental group, 14/12 rats of group of
positive control. To obtain histological data, animals were randomly selected from sham-operated
(n = 5), the control (n = 5), and the experimental (n = 5) groups at day 5 after modeling GCI. The animals
were anesthetized with ethyl ether and the brains were sampled. Registration of LCBF, arterial
blood pressure and heart rate were determined in five sham-operated rats, nine rats of the control
group, and 10 rats of the experimental group. Measurement of hemorheological parameters was
examined in five sham-operated rats, six rats of the control group, and six rats of the experimental
group. Measurement of vasodilator activity of endothelium was determined in five sham-operated
rats, eight rats of the control group, nine rats of the experimental group, and six rats of the positive
control group. Measurement of isolated carotid artery tonus in vitro was carried out in seven intact
rats. The IQ-1S effects on PT, aPTT, TT, and Fbg were studied in five sham-operated rats, eight rats of
control group, and nine rats of the experimental group.
4.7. Neurological Deficit Evaluation
Neurological status of animals was examined by experimenter unaware of group the animals
were assigned to. Neurological deficit in GCI model was evaluated based on McGraw stroke index
scale [78] in our modification. The following parameters were assessed to evaluate neurological status:
(1) spontaneous motor activity (normal—0 point, attenuated motor activity or stiffness, shakiness of
gait, bradykinesis—1 points, elevated or absent motor activity or disorientation—2 points); (2) tail
flick reflex (normal—0 point, attenuated—1 point, absent—2 points); (3) right front limb withdrawal
reflexes (normal—0 point, attenuated—1 point, absent—2 points); (4) left front limb withdrawal
reflexes (normal—0 point, attenuated—1 point, absent—2 points); (5) right rear limb withdrawal
reflexes (normal—0 point, attenuated—1 point, absent—2 points); (6) left rear limb withdrawal
reflexes(normal—0 point, attenuated—1 point, absent—2 points); (7) response to sound (normal—0
point, attenuated—1 points, absent or elevated—2 points); (8) tremor, seizures (absence—0 point,
or presence—2 points); (9) muscle tones of the trunk and limbs (normal—0 point, attenuated—1 point,
elevated or absent—2 points); (10) signs of ptosis (absent—0 point, unilateral—1 point, bilateral—2
points). Neurological deficit was characterized by sum of scores from all parameters. Besides, rates of
animals with severe (score 6 and more), moderate (score 3–5), and mild (score less than 2) were
determined in each group.
4.8. Histology Study
To study morphology of hippocampal neurons, rat brain was fixed in 10% neutral buffered
formalin. After fixation, frontal brain segment, corresponding to coordinates from 2.80 mm to 4.30 mm
relative to bregma according to rat brain stereotaxic atlas [79], were embedded in paraffin according to
the commonly accepted method, sliced with rotary microtome HM 340E into 5 µm slices, and stained
with hematoxylin and eosin. Biological material was processed with automatic STP 120 Spin Tissue
Processor (Thermo Fisher Scientific, Waltham, MA, USA). Photodocumenting was performed with
Carl Zeiss Axio Lab.A1 microscope and Axio Cam ERC5S camera. Histoquantitative study consisted
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of determining neuronal density by calculating number of neurons per 1 mm2 area of the slice and
determining percentage of morphologically unchanged neurons in accordance with existing assessment
criteria: clearly defined nucleus of elliptical or round shape; well identifiable nucleoli at the center of
the nucleus; nucleus slightly darker than surrounding neuropil; and cytoplasm of a neuron is clearly
demarcated from the surrounding neuropil. Neurons with irreversible ischemic/reperfusion injury
were identified by morphological changes such as karyopyknosis, eosinophilic cytoplasm, shrunken
cell body and pericellular edema [80].
4.9. Antioxidant Activity Measurement
To determine the lipid peroxidation products in brain tissue at day 5 after GCI, rats under
ether anesthesia were decapitated; the brain was removed; one hemisphere was sampled;
ethylenediaminetetraacetic acid was added to the sample at a rate of 1 mg/g of the tissue; and the
sample was homogenized. Then, lipids were extracted from 250 mg of homogenate of the brain
tissue by using the mixture of heptane-isopropanol (1:1) at a ratio of 1:20 (by mass) for 15 min. Phase
disengagement was performed with 0.1 N HCl. The top (heptane) phase was sampled to determine
the content of diene conjugates and triene conjugates. The contents of diene conjugates and triene
conjugates were assessed based on absorption peaks at 232 and 275 nm characteristic of double and
conjugated double bonds, respectively [81]. The content of diene and triene conjugates was determined
on a Cary Win UV spectrophotometer at 232 nm and 275 nm, and expressed as OD232/mg lipids and
OD270/mg lipids, correspondingly. Heptane was used as comparison solution.
Quantitative assessment of lipid content in hexane phase was done gravimetrically.
4.10. Antiradical Activity Measurement
Antiradical activity of IQ-1S was assessed in vitro in the model reaction of interaction with DPPH,
a stable chromogen radical [82]. In the visible spectrum, DPPH in organic solvents has maximum
absorption at 515–520 nm, which progressively decreases and disappears with the conversion of
the compound to non-radical form on the interaction with antioxidants. Kinetic curves expressed
as optical density variation for control and test samples were recorded using a spectrometer Cary
50 immediately after mixing DPPH (0.25 mM) with a solvent (control sample) or solution of test
compound (0.25 mM) at volumetric ratio of 1:1. Ethanol, acetone, ethyl acetate, and acetonitrile were
used as solvents. For each solvent, the experiments were performed three to six times. Antioxidant
3,5-dibutyl-4-hydroxytoluene (also known asionol, dibunole, or butylatedhydroxytoluene) was used
as a comparison agent. For quantitative characteristics of antiradical activity, reaction rate of DPPH
with test compounds was calculated based on the initial kinetic curve slope [83]. According to the
method, antiradical activity strongly correlates with the antioxidant activity determined by this assay
and can be used for quantitative assessment of antioxidant properties [83].
4.11. Registration of LCBF, Arterial Blood Pressure, and Heart Rate
In a designated series of experiments, the effects of IQ-1SonLCBF, heart rate, and mean arterial
blood pressure in anaesthetized rats were studied on day 5 after GCI. For induction of anesthesia,
diethyl ether was administered. General anesthesia was maintained with sodium thiopental i.v.
through the catheter in femoral vein (at a dose of 25 mg/kg/h).
LCBF was assessed by laser-Doppler flowmetry within the primary visual cortex V1M (primary
visual cortex, monocular area). The level of LCBF was registered using a data acquisition system
MP150 with LDF100C module and a TSD144 fiber-optic needle-type surface sensor (25 mm × 1 mm
(d)). The skin was moved apart with a retractor, and a hole with a diameter of 1.5 mm was drilled into
the skull without breaking the dura mater integrity. The sensor for measuring the LCBF was installed
using a special balancer-holder tool.
Mean arterial blood pressure was registered using a data acquisition system MP150 with MPMS200
and probe TSD280 femoral artery. Heart rate was calculated based on the curve of blood pressure
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changes. The obtained data were processed with “AcqKnowledge 4.3” software (Biopac Systems, Inc.,
Goleta, CA, USA).
4.12. Measurement of Hemorheological Parameters
Blood was sampled from the catheterized right common carotid artery and stabilized with a 1%
aqueous solution of K2EDTA (20 µL of solution per 1 mL of blood) in Teflon-coated tubes for immediate
analysis. Whole blood and plasma viscosities were measured using a rotational viscometer LVDV-II+
Pro, CP40 at 36 ◦C at shear rates ranging from 10.5 to 450 s−1. The plasma viscosity was measured at a
shear rate of 450 s−1. The hematocrit was measured using the gravimetric method by centrifuging blood
samples in glass capillaries at 1300 g for 20 min; the results are expressed as a percentage. Red blood
cell (RBC) aggregation and deformability were measured with RheoScanAnD-300. The critical time of
aggregation (T1/2) (Ct) and the critical stress (Cs) of aggregation were used to characterize the RBC
aggregation. The elongation index (EI) was used to characterize RBC deformability [84,85].
4.13. Measurement of Vasodilator Activity of Endothelium
To evaluate functional state of the vascular endothelium, animals were implanted with a catheter
in the right femoral artery for registration of arterial blood pressure and a catheter in the right femoral
vein for bolus introduction of pharmacological agents. Arterial blood pressure was restarted using a
data acquisition system MP150 with MPMS200 and TSD280 sensor. The obtained data were processed
with “AcqKnowledge 4.3” software. Hypotensive reaction of systemic arterial blood pressure in
response to endothelium-dependent vasodilation and endothelium-independent vasodilation were
registered according to the method of Laursen et al. [86] in our modification. Endothelium-dependent
vasodilation mediated by NO-synthase activation was triggered by bolus i.v. administration of Ach at
a dose of 40 µg/kg; area above the curve of blood pressure decrease SAch was calculated and expressed
in mm Hg•sec. Endothelium-independent vasodilation was triggered by i.v. bolus introduction of SNP
at a dose of 30 µg/kg with calculation of SSNP by the same approach. To quantitatively characterize
vasodilatory activity of the vascular endothelium, the IVA was used, calculated as ratio of SAch/SSNP.
4.14. Measurement of Isolated Carotid Artery Tonus In Vitro
Wistar rats were euthanized by asphyxiation in a CO2 chamber. Carotid arteries were dissected,
cleaned of adherent fat, and de-endotelized with means of 3-mm rings of carotid arteries were prepared
and placed in an organ chamber of Myobath II between two stainless hooks for isometric recording.
One hook was attached to the bottom of the bath, and the other was connected with the isometric
force transducer. Rings were stretched to a resting tension of 1 g and equilibrated for 1 h. In all
experiments, carotid artery rings were preconstricted with 30-µM phenylephrine (PE) after the tone of
the vascular preparations was stabilized. IQ-1S was studied at concentrations ranging from 0.001 to
100 µM. Test substance was diluted in 100% DMSO to achieve the concentration of 0.01 M. Further
concentrations were obtained by subsequent dilution in 100% DMSO. Final concentration of DMSO in
solution was 1% and did not significantly affect contractile activity of vascular rings.
4.15. Measurement of the Pasma Hemostasis Parameters
Prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT),
and fibrinogen level (Fgn) were identified to assess the state of plasma hemostasis in platelet-poor
plasma. The blood was centrifuged to receive platelet poor plasma at centrifugation speed of 1300 g for
20 min. The study of plasma hemostasis parameters was performed using the KG-4 coagulometer with
test assays “PT-test” (prothrombin time), “Techplastin-test” (activated partial thromboplastin time),
“Thrombo-test” (thrombin time), “Fibrinogen-test” (fibrinogen) (“Technology-Standard”, LLC, Russia).
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4.16. Statistical Analysis
Statistical processing was performed with Statistica 8.0 software. All results are expressed as
mean ± SEM. Group variation was assessed with Kruskal–Wallis test. Significant difference between
were assessed by Fisher’s exact test for severity of neurological deficit, by Mann–Whitney U-test
for average rate of neurological deficit and infarct volume, by Student’s t-test for histological and
antiradical investigation. Compliance of the sample with normal distribution was evaluated with
Shapiro–Wilk’s W test and Kolmogorov–Smirnov & Lilliefors test. Values were considered statistically
significant when p was < 0.05.
5. Conclusions
IQ-1S at a dose of 50 mg/kg demonstrated pronounced neuroprotective properties in the model
of GCI when administered i.g. in a treatment-and-prophylactic regime. Neuroprotective effect was
observed as a significant decrease in the loss of the pyramid neurons in the CA1 hippocampal area
highly sensitive to ischemia as well as a clearer reduction of neurological deficit after GCI episode.
Regarding the neuroprotective effect, IQ-1S met or exceeded citicoline used as a positive control.
We suggest that the beneficial effects of IQ-1S on stroke outcome could be a combined result of
JNK inhibition by the parent compound in brain tissue, NO generation during its bioconversion,
their antioxidant and antiradical activity, improvement of microcirculation in cerebral tissue as result of
vasodilatory activity, and decrease of blood viscosity and endothelial dysfunction. Our results suggest
that IQ-1S may be considered as a neuroprotector with a multitarget mechanism of action.
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